Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed

Ad hoc announcement pursuant to Art. 53 LR

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.